{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.6","value":"151"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"description":"Cmax was defined as the maximum observed plasma concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).","id":"OG000","title":"Retifanlimab 500 mg"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) Evaluable Population: all participants who received at least 1 dose of study drug and provided a Baseline and at least 1 postdose serum sample (1 PK measurement)","reportingStatus":"POSTED","timeFrame":"pre-infusion on Day 1 of Cycles 1, 2, 4, 6, and 7; 10 minutes and 4 hours post-infusion on Day 1 of Cycles 1 and 6","title":"Cmax of Retifanlimab","type":"SECONDARY","unitOfMeasure":"milligrams per Liter (mg/L)"}